

AMENDMENTS TO THE CLAIMS

1-40. (Canceled).

41. (Currently Amended) A method for detecting a virus that is not a plus-strand RNA virus in a sample, comprising:

- a) providing:
  - i) a sample;
  - ii) cells susceptible to said virus that is not a plus-strand RNA virus, wherein said not a plus-strand virus is selected from the group consisting of influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, and metapneumovirus; and
  - iii) at least one protease inhibitor;
- b) contacting said cells and said sample in the presence of said protease inhibitor to produce contacted cells, wherein replication of said virus that is not a plus-strand RNA virus in said contacted cells is not reduced relative to replication of ~~said virus that is not a plus-strand RNA virus in cells not contacted with said protease inhibitor, and wherein replication of a coronavirus plus-strand RNA virus in said cells contacted with said protease inhibitor is reduced relative to replication of said plus-strand RNA virus in cells not contacted with said protease inhibitor, wherein said coronavirus replication is at least 25% lower than said not a plus-strand RNA virus replication .~~

42. (Canceled)

43. (Currently Amended) The method of Claim 41 [[42]], wherein said influenza virus is chosen from influenza A, influenza B, and influenza C.

44. (Currently Amended) The method of Claim 41 [[42]], wherein said parainfluenza virus is chosen from parainfluenza 1, parainfluenza 2, parainfluenza 3, and parainfluenza 4.

45. (Currently Amended) The method of Claim 41 [[42]], wherein said adenovirus is chosen from adenovirus 2, adenovirus 3, adenovirus 4, adenovirus 5, adenovirus 7, adenovirus 9, adenovirus 12, adenovirus 17, and adenovirus 40.

46. (Canceled)

47. (Currently Amended) The method of Claim 41 [[46]], wherein said coronavirus comprises SARS-coronavirus.

48-51. (Canceled)

52. (Previously Presented) The method of Claim 41, wherein said protease inhibitor is contained in a composition comprising a cyclodextrin.

53. (Currently Amended) The method of Claim 52, wherein said cyclodextrin comprises sulfobutyl ether beta-cyclodextrin sodium ~~is Captisol~~.

54. (Previously Presented) The method of Claim 41, wherein said protease inhibitor is selected from Actinonin, Glycyrrhizin, and E64D.

55. (Withdrawn) A method for inhibition of human coronavirus 229E replication comprising:

- i) providing a composition comprising the protease inhibitor E64D and Captisol; and
- ii) contacting a cell permissive for 229E replication with said composition under conditions suitable for inhibiting 229E replication in said cell.

56-67. (Canceled)

68. (Withdrawn) The method of Claim 55, wherein said cell permissive for 229E replication is selected from the group consisting of a human embryonic kidney (HEK)-293 cell, a HEK-293T cell, a Huh-7 cell, a mink lung cell, a Mv1Lu cell, a primary rhesus monkey kidney (pRHK) cell and a primary cynomolgus monkey kidney (pCMK) cell.